• Blog
  • News
In March 2020, when the World Health Organization declared the new coronavirus pandemic, the Administrative Council for Economic Defense quickly mobilized to institute agile and assertive measures to guarantee a safe environment for all municipality employees and employees. A year passed, and during this period, the measures were consolidated, supported in a spirit of collective assistance and support.
Administrative Council for Economic Defense published the concentration act's announcement involving the biopharmaceuticals AstraZeneca PLC and Alexion Pharmaceuticals in the Official Gazette on the 10th of March.
In the judgment session on the 24th of February, CADE approved, with restrictions, a concentration act that provides for the transfer of assets from Plamed to Hapvida. The authorisation of the operation was conditioned to the signing of a Concentration Control Agreement.
Administrative Council for Economic Defense approved the acquisition of a set of medicines from Takeda Pharmaceuticals International by Hypera on the 20t of January. The deal involves the holding and commercialization, by Hypera, of product lines such as Dramin, Nebacetin, Neosaldina, Eparema, Xantinon, Nenê-Dent, Albocresil, Venalot, Ad-Til, Alektos and Nesina. The endorsement of the operation was conditioned to the signing of an agreement, which removes competitive concerns.
On the occasion of World Competition Day CUTS International and CUTS Institute for Regulation & Competition (CIRC) held a webinar, which discussed Competition Policy and Access to Healthcare. The session was moderated by Rashid S. Kaukab, Executive Director, CUTS International, Geneva.
We are pleased to invite you to attend the Webinar titled “Access to Healthcare and Competition Policy,” jointly organised by CUTS International (Geneva) and CUTS Institute for Regulation and Competition (New Delhi) on the eve of the World Competition Day.
The European Commission fined pharmaceutical companies Teva and Cephalon € 60.5 million for a mutual agreement between the companies to delay the market launch of a cheaper generic version of Cephalon's sleep disorder drug, modafinil, for several years after expiration major Cephalon patents. The fines imposed by the Commission on Teva and Cephalon are € 30 million and € 30.5 million, respectively.
The document aims to ensure the availability of inexpensive essential drugs for patients.

The Russian competition commission, together with the Russian Ministry of Health, is working on a document that allows indexing prices for vital drugs, the production of which has become unprofitable.
During a challenging year, M&A activity in pharmaceutical markets was lower than experts estimated. Also, there were not many megadeals in Q1 and Q2 compared with 2019 (where the value of the largest deal was $99.5 billion). The biggest deals in the first half of 2020 were Thermo Fisher Scientific / Qiagen ($11.5 billion, COVID-19), Gilead Sciences / Forty Seven ($4.9 billion, oncology), Gilead Sciences / Pionyr Immunotherapeutics ($1.7 billion, oncology), Novo Nordisk / Corvidia ($2.1 billion, cardiometabolic diseases), Eli Lilly / Dermira ($1.1 billion, immunology, dermatology).
Expert at the BRICS Competition Centre
The Federal Antimonopoly Service of Russia plans to initiate a case for the sale of express tests for coronavirus to the population in retail chains, testing for COVID-19 should be carried out by specialists, said the head of the department Igor Artemyev.
The General Superintendence of the Administrative Council for Economic Defense sent the merger act for analysis by the autarchy court regarding the acquisition, by the pharmaceutical company Hypera, of the development, manufacture, marketing, distribution and sale of the Buscopan product family in Brazil - currently owned by Boehringer Ingelheim International.
FAS Russia Deputy Head Andrey Tsyganov spoke about the activities of the antimonopoly service during the COVID-19 crisis and discussed the development of competition with experts and representatives of Russian companies
The Competition Commission of South Africa has announced that it welcomes the decision of the Competition Tribunal that confirms the settlement agreement between the Commission and Cape Town-based company - Caprichem.
The Administrative Council for Economic Defense has published a brief information note in which it deals with the collaboration between companies in the face of the Covid-19 crisis. The document provides guidance on the parameters recommended in the elaboration of strategies to combat the pandemic and on the procedures available for economic agents to obtain CADE's statement.
The issues of price regulation for vital medicines remains a heated issue for all participants in the healthcare system especially when it comes to the mechanisms that are necessary to ensure the presence of drugs on the pharmaceutical market.
Competition Authorities’ approaches to global economic concentration: How to respond jointly to the challenges of a growing global pharmaceutical oligopoly?
Advocate General of the European Court of Justice, Juliane Kokott expressed the view that the judicial authority should support the decision of UK Competition and Market Authority that transactions to delay the entry into the market of generics (pay-for-delay) between GlaxoSmithKline and other companies are in violation of antitrust laws, FirstWord Pharma reports.
The Federal Antimonopoly Service (FAS) of Russia has recorded complaints from citizens about the rise in the price of several products amid a decline in imports from China due to coronavirus. Mr Andrey Tsyganov, the deputy head of the FAS Russia has commented on the situation with the following statement - "We see reports about prices rising for some products, but not from reports of our territorial administrations, but the media and citizens".
In the interview to The Wall Street Journal, Assistant Attorney General Makan Delrahim said that the Justice Department is preparing to research and investigate the generic drug industry and even go as far as filing cases for allegedly fixing prices. The department has been investigating possible criminal conduct by generic drug companies for years, but there has been little action so far.
In July 2019 the head of the Federal Antimonopoly Service Igor Artemiev at a meeting with Russian President Vladimir Putin said that in Russia, the problem of cartels is now most acute in the pharmaceutical industry. Three months later, we can see the progress in the battle with the cartels